Anika Therapeutics (ANIK) Tops Q4 EPS by 28c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.59 +2.75%
Revenue Growth %: +3.5%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +3.5%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.05, $0.28 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $43 million versus the consensus estimate of $41.4 million.
GUIDANCE:
Anika Therapeutics sees FY 2024 revenue of $168-173 million, versus the consensus of $179.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- Cerebras Systems posts 94% revenue jump, announces OpenAI deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
